The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for ...

The U.S. Food and Drug Administration has approved Organon's Vtama (tapinarof) 1% cream for an additional indication -- the ...

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...

The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).

The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.

The US Food and Drug Administration (FDA) has approved tapinarof cream, 1% for the treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older. An aryl ...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD ...

The approval was based on data from 2 multicenter, randomized, double-blind, vehicle-controlled trials, ADORING 1 and ADORING 2.

Shares in Galderma climbed after the company said the U.S. Food and Drug Administration approved its drug Nemluvio for the treatment of patients with atopic dermatitis. Shares in Galderma were 3.2% ...

Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug ... atopic dermatitis patients in my practice who are seeking relief from burdensome itch and lesions.” The FDA also ...

The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.